期刊
NANO LETTERS
卷 22, 期 14, 页码 5898-5908出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.nanolett.2c01850
关键词
Platinum II vs Platinum IV; biomimetic materials; block polypeptides; nanomedicine; cancer
类别
资金
- National Institutes of Health (MIRA) [R35GM127042]
- Dr. Reddy's laboratory, India
Loading Pt(IV) into genetically engineered nanoparticles can enhance the therapeutic efficacy of platinum drugs, potentially yielding more effective platinum-drug nanoformulations.
The development of platinum(Pt)-drugs for cancer therapy has stalled, as no new Pt-drugs have been approved in over a decade. Packaging small molecule drugs into nanoparticles is a way to enhance their therapeutic efficacy. To date, there has been no direct comparison of relative merits of the choice of Pt oxidation state in the same nanoparticle system that would allow its optimal design. To address this lacuna, we designed a recombinant asymmetric triblock polypeptide (ATBP) that self-assembles into rod-shaped micelles and chelates Pt(II) or enables covalent conjugation of Pt(IV) with similar morphology and stability. Both ATBP-Pt(II) and ATBP-Pt(IV) nanoparticles enhanced the half-life of Pt by & SIM;45-fold, but ATBP-Pt(IV) had superior tumor regression efficacy compared to ATBP-Pt(II) and cisplatin. These results suggest loading Pt(IV) into genetically engineered nanoparticles may yield a new generation of more effective platinum-drug nanoformulations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据